DBV Technologies previously announced that it had raised €166.7 million in gross proceeds from the full exercise of warrants ...
Châtillon, France, January 16, 2026DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of ...
AMF Regulated InformationChâtillon, France, January 7, 2026Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFDBV ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...
On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...
A recently announced partnership between global food giant Nestlé Group and DBV Technologies (DBVT), a France-based specialty biopharmaceutical company, is attracting investor attention for its focus ...
DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback